Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Ovid Therapeutics Inc. | ovid-ex312_8.htm |
| EX-31.1 - EX-31.1 - Ovid Therapeutics Inc. | ovid-ex311_9.htm |
| EX-23.1 - EX-23.1 - Ovid Therapeutics Inc. | ovid-ex231_6.htm |
| EX-10.16 - EX-10.16 - Ovid Therapeutics Inc. | ovid-ex1016_797.htm |
| EX-10.15 - EX-10.15 - Ovid Therapeutics Inc. | ovid-ex1015_795.htm |
| EX-10.13 - EX-10.13 - Ovid Therapeutics Inc. | ovid-ex1013_750.htm |
| EX-4.3 - EX-4.3 - Ovid Therapeutics Inc. | ovid-ex43_544.htm |
| 10-K - 10-K 2019 - Ovid Therapeutics Inc. | ovid-10k_20191231.htm |
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Ovid Therapeutics Inc. (the “Company”) for the year ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his or her knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: March 11, 2020
|
By |
/s/ Jeremy M. Levin |
|
|
Jeremy M. Levin Chief Executive Officer |
Date: March 11, 2020
|
By |
/s/ Timothy Daly |
|
|
Timothy Daly Executive Vice President, Finance and Corporate Controller |